^
    4ms
    Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov)
    P=N/A, N=3, Terminated, Mustang Bio | N=331 --> 3 | Trial completion date: Jul 2041 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Apr 2041 --> Apr 2024; Business Reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    MB-106 • MB-102
    11ms
    Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. (PubMed, Mol Ther Oncolytics)
    The CD33/CD123 bispecific CAR T cells were able to control acute myeloid leukemia (AML) in a xenograft AML mouse model similar to monospecific CD33 and CD123 CAR T cells while showing no on-target off-tumor effects. Based on our findings, human CD33/CD123 bispecific CAR T cells are a promising cell-based approach to prevent AML and support clinical investigation.
    Journal • CAR T-Cell Therapy
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression • IL3RA expression
    |
    MB-102
    almost2years
    Significantly Targeting Acute Myeloid Leukemia with the Combination of Anti-CD123 CAR Modified Expanded Natural Killer Cells and Romidepsin (TCT-ASTCT-CIBMTR 2023)
    Results Anti-CD123 CAR expressed on more than 96% of expanded NK cells after CAR mRNA electroporation (Fig.1A) and lasted for about one week. Anti-CD123 CAR NK showed significantly enhanced in vitro cytotoxicity against CD123 + KG1a and HL-60 with significantly enhanced IFN-
    IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • NKG2D (killer cell lectin like receptor K1)
    |
    CD123 expression
    |
    Istodax (romidepsin) • MB-102
    almost4years
    Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous
    almost5years
    Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2019 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Nov 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous